ArticleGlomerular diseases
Clinicopathologic Characteristics of Intraglomerular Malignancy in Kidney Biopsies.
Article in Glomerular diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Intraglomerular malignancy (IGM) is a rare finding, with current data limited to case reports and small, often postmortem, series. This study aimed to characterize the clinicopathologic features of kidney biopsy cases with IGM. Methods: Renal biopsy cases diagnosed with IGM from January 2000 to June 2023 at Cedars Sinai Medical Center were retrospectively reviewed. Demographic data, clinical characteristics, and pathologic data were collected, and cases were divided into hematologic (HEME) versus non-hematologic (non-HEME) malignancy. Results: We identified 9 patients with IGM. Five were hematolymphoid in origin, and 4 were from metastatic solid tumor (2 carcinomas from the lung, 1 neuroendocrine tumor of likely lung origin, and 1 from the head and neck). All patients presented with proteinuria and hematuria, and 89% had renal dysfunction. The median serum creatinine was 2.9 (IQR 1.7-5.7) mg/dL. All non-HEME patients had an established malignant diagnosis at the time of kidney biopsy, whereas all HEME cases were initially or concurrently diagnosed at the time of biopsy. Two of the non-HEME biopsies showed extracapillary hypercellularity due to malignant cells, a feature not seen in HEME cases. Of the 8 patients with follow-up available, 7 (88%) died within a median of 69 (IQR 4-161) days. Conclusion: IGM is a rare presentation of disseminated malignancy, often indicating advanced disease with poor prognosis. Nephropathologists should be aware of IGM as a histologic mimicker of endocapillary hypercellularity or cellular crescent formation. Similarly, the provision of complete clinical history is critical for accurate biopsy assessment and to avoid this diagnostic pitfall. Given its high mortality rate and the short interval between tissue diagnosis and death, the identification of IGM should prompt urgent medical attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.